Search

everythinglearnresearchcommunity

for

Search:↓

KX-826/pyrilutamide is undergoing an additional one-year safety and efficacy trial in China after a six-month study. Some participants speculate on the reasons for the extended trial and discuss the potential of other treatments.

The conversation is about trying dutasteride mesotherapy for hair loss, with concerns about its effectiveness and potential side effects compared to finasteride. The user is considering this treatment available in California.

The user is considering starting finasteride for hair loss but is concerned about potential side effects due to their estradiol levels being near the upper limit. They have consulted a doctor who confirmed their levels are okay to start the treatment.

The conversation discusses the effectiveness of dutasteride injections for hair loss, often paired with oral minoxidil and oral finasteride/dutasteride. The user is seeking information on U.S. clinics offering this treatment.

The conversation discusses the ineffectiveness of tablet forms of dutasteride for hair loss due to poor absorption compared to soft gel capsules. It suggests switching to FDA-approved soft gel capsules for better results, as tablets may not adequately suppress DHT levels.

People are discussing their reactions if PP405 fails in phase 3 trials, with some expressing skepticism and others holding onto hope for future treatments like GT20029 and Breezula. Many mention continuing with existing treatments like minoxidil and finasteride, while others express disappointment and consider alternative solutions.

Dr. Kang-Yell Choi's company, CK Regeon, is developing a drug called KY19382 for hair regeneration, which involves creating fine wounds to activate stem cells. The drug is in the formulation development stage, targeting markets like the US and Korea.

The conversation is about when GT20029, a hair loss treatment, might be available on the grey market, with users discussing the challenges of compounding it and speculating it might be available after phase 2 results, similar to pyri. Specific treatments mentioned are pyri, RU58841, and GT20029.

PTD-DBM therapy for hair loss is being developed by Dr. Kang-Yell Choi, with human testing planned in South Korea. Some clinics in the U.S. offer PTD-DBM/valproic acid therapy, but it hasn't completed trials yet.

The user is taking 0.5mg finasteride and 0.5mg Loniten orally daily, using Eucapil twice weekly, and Minoxidil foam once daily for hair loss. They believe Eucapil effectively stops hair loss despite side effects like breast growth.

The conversation discusses using RU58841, a research chemical, for hair loss treatment. The user plans to use it due to side effects from finasteride and minoxidil, despite skepticism about its effectiveness and lack of FDA approval.

Taking dutasteride with a meal containing fat may improve absorption, but consistency in routine is more important than timing. Minor variations in absorption won't significantly affect efficacy due to dutasteride's long half-life.

The conversation is about the possibility of obtaining Pyrilutamide, a hair loss treatment, once it becomes available in China, despite it not being approved by the US FDA yet. The user wants to use Pyrilutamide along with other treatments.

Efforts to find a Canadian dermatologist in the US to prescribe H&W's topical finasteride for hair loss. The user is willing to fund a crowd-share effort to identify prospects.

The conversation is about a user offering free unused Eucapil after switching to finasteride for hair loss treatment. The user did not use Eucapil and is willing to give it away locally or ship it if costs are covered.

A user is seeking an online prescription for finasteride after local dermatologists recommended alternatives like vitamins, caffeinated shampoo, and minoxidil. Another user suggests using Mobidoctor to obtain the prescription.

TDM-105795 showed better efficacy and safety in trials for hair loss, with a higher hair count improvement compared to GT20029 and HMI 115, but it's not as widely discussed. The user is questioning why this is the case.

User experienced high E2 levels after taking finasteride and sought advice on lowering E2 with supplements like Tonkat ali, Fadogia, and Boron. They also used DIM, zinc, and magnesium but avoided using an AI.

Using Dutasteride as a hair loss treatment and its potential benefits, including availability in certain countries without a prescription and lower side effects than Minoxidil or RU58841.

Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.

The user experienced side effects from ecklonia cava similar to those reported with finasteride, including depression, brain fog, anxiety, and testicular pain. Despite these issues, the user is still considering using topical finasteride in the future.

France is considering reviewing finasteride and dutasteride due to concerns about their safety, but a ban in the EU is unlikely due to regulatory hurdles. Many users express frustration over the potential ban, emphasizing the effectiveness of finasteride for hair loss and criticizing the influence of anecdotal evidence on public health policy.

Pyrilutamide's mainstream product release date is discussed. Side effects found in studies are also questioned.

The conversation discusses using estradiol mesotherapy to replicate hormone replacement therapy results while minimizing systemic exposure. It also covers the use of Spironolactone cream, which reportedly has no systemic side effects, and the potential risks of using bicalutamide and Spironolactone in men.

The conversation is about the approval of Clascoterone (Winlevi) in Canada for hair loss treatment. One user expressed skepticism about its effectiveness due to low concentration.

The user is treating male pattern baldness with oral minoxidil, ketoconazole, derma rolling, rosemary oil, and topical minoxidil, and is considering adding finasteride. They are debating between three finasteride dosing strategies: 1mg daily, 1.25mg every other day, or 1.25mg five days a week, focusing on efficacy, safety, and cost.

PP405 is suspected to be a scam, with users doubting its legitimacy and effectiveness. Many recommend using proven treatments like finasteride and minoxidil.

A user discusses the potential of caffeine and DMG in shampoo for treating hair loss, citing a pending patent and personal plans to test it. They find it more convenient than using minoxidil, tretinoin, and microneedling.

A user shared a new hair loss treatment protocol including topical dutasteride, latanoprost, caffeine, minoxidil, tretinoin, and triamcinolone acetonide. Others discussed the effectiveness and availability of these treatments, with some suggesting simpler oral alternatives.

Veradermics' new hair loss treatment, VDPHL01, is likely a modified release oral minoxidil, which has received $75 million in funding for clinical trials. Despite skepticism about investing in a known treatment, some believe it could offer improved efficacy and reduced side effects.